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Abstract
The proliferation of pancreatic duct-like CK19+ cells has implications for multiple disease states including pancreatic cancer
and diabetes mellitus. The in vitro study of this important cell type has been hampered by their limited expansion
compared to fibroblast-like vimentin+ cells that overgrow primary cultures. We aimed to develop a screening platform for
duct cell mitogens after depletion of the vimentin+ population. The CD90 cell surface marker was used to remove the
vimentin+ cells from islet-depleted human pancreas cell cultures by magnetic-activated cell sorting. Cell sorting decreased
CD90+ cell contamination of the cultures from 34620% to 1.360.6%, yielding purified CK19+ cultures with epithelial
morphology. A full-factorial experimental design was then applied to test the mitogenic effects of bFGF, EGF, HGF, KGF and
VEGF. After 6 days in test conditions, the cells were labelled with BrdU, stained and analyzed by high-throughput imaging.
This screening assay confirmed the expected mitogenic effects of bFGF, EGF, HGF and KGF on CK19+ cells and additionally
revealed interactions between these factors and VEGF. A serum-free medium containing bFGF, EGF, HGF and KGF led to
CK19+ cell expansion comparable to the addition of 10% serum. The methods developed in this work should advance
pancreatic cancer and diabetes research by providing effective cell culture and high-throughput screening platforms to
study purified primary pancreatic CK19+ cells.
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Introduction
The pancreas is a complex organ containing multiple
interspersed cell types with diverse exocrine and endocrine
functions. Established protocols exist for isolating, studying and
transplanting relatively pure cultures of endocrine islet cells
[1,2,3], but the culture of enriched CK19-positive ductal cells
has proven challenging. Human CK19-positive cells are an
interesting cell population [4] as they have been shown to
proliferate in several disease states, including pancreatic ductal
adenocarcinoma [5] and diabetes [6]. Some groups have also
suggested that cells with a ductal phenotype, potentially centroa-
cinar cells [7], have the potential to express measurable amounts
of insulin in vitro [8,9,10,11,12] or in vivo after pancreas injury
[12,13]. However, the results from lineage tracing experiments
that could prove the conversion of duct cells to b-cells have mostly
been negative [14,15,16,17]. Multiple groups have tried to
maintain human duct cells in long-term culture [10,18,19], but
rapidly dividing vimentin-positive cells quickly overgrow adherent
cultures of mixed exocrine cells [18,20]. In addition, most
pancreatic duct cell culture protocols require the use of serum-
containing medium, which is undesirable for research or
therapeutic cell culture because serum is undefined, suffers from
high batch-to-batch variation and may contain dangerous
contaminants that are problematic for transplantation applications
[21,22]. Improved methods to separate exocrine cell populations
and to culture them in defined optimized media are needed to
enable studies of duct cell biology.
One reported method to obtain 93,97% pure CK19+ cell
cultures isolated pancreatic cells expressing the carbohydrate
antigen 19-9 (Ca19-9) [23]. However, the cell phenotypes
obtained after 7 days of culture were not quantified and the
Ca19-9 enriched cells expanded poorly [24]. Since vimentin-
positive cells are the main competing population, an alternative
approach would be to selectively remove this population. This
negative cell sorting strategy would have the advantage of leaving
the cells of interest free from surface antibodies and magnetic
beads that may affect cell behaviour [25,26]. The in vitro
differentiation potential of fibroblast-like cells expanded from
adult human pancreatic tissue resembles the differentiation
potential expected for mesenchymal stem cells, expressing markers
including CD90 and capable of chondrogenic or osteogenic
differentiation [20]. CD90.1-positive cells enriched from rat
pancreatic tissue adopt a fibroblast-like phenotype in culture and
express much lower levels of duct markers than CD90.1-depleted
cells [27].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33999We present a novel method to obtain purified human CK19-
positive cell cultures from mixed pancreatic exocrine tissue and to
quantify their proliferation in a high-throughput assay. Depletion of
CD90-expressing cells successfully eliminated most fibroblast-like
cells from the cultures. High-throughput imaging of the CD90-
depleted cultures in 96-well plates allowed the multifactorial testing
of the effects of five reported duct mitogens on apoptosis, expansion
and proliferation. This led to the development of a serum-free
medium to replace the use of serum and provide defined culture
conditions for pancreatic duct cell culture research.
Methods
Cell culture
Islet-depleted pancreatic cell aggregates from human donors (10 in
total; age 39619 years; body weight 72613 kg) were kindly provided
by Dr. Garth Warnock and Dr. Ziliang Ao at the Ike Barber Human
Islet Transplant Laboratory (Vancouver, BC, Canada). Pancreata
were obtained with the written informed consent of family members
under the approval of the University of British Columbia Clinical
Research Ethics Board. Cell clusters received on day 0 were washed
twice in CMRL medium with 10% fetal bovine serum, 100 units/mL
penicillin and 100 mg/mL streptomycin (all from Invitrogen,
Carlsbad, CA), referred to as CMRL+10% FBS medium. Clusters
were then dispersed or seeded overnight in CMRL+10% FBS
medium at 1 mL packed cell volume (PCV)/cm
2 (PCV tubes, Techno
Plastic Product, Trasadingen, Switzerland) in tissue culture-treated
flasks (Sarstedt,Nu ¨mbrecht, Germany) before magnetic-activated cell
sorting (MACS) on day 1. Unsorted or sorted cells were seeded at
1.25610
5 cells/cm
2 in 0.32 mL/cm
2 CMRL+10% FBS medium in
plates containing 0.32 mL/cm
2 pre-incubated medium and cultured
at 37uC, 5% CO2 and 90% humidity. Live cells were enumerated by
trypan blue exclusion using a Cedex cell counter (Roche Innovatis,
Bielefeld, Germany). The unsorted and MACS-sorted cultures were
maintained in CMRL+10% FBS medium for 8 days, with medium
exchanges on days 2, 5 and 7. For serum-free assay development and
screening, the cultures were shortened to 6 days with medium
exchanges on days 2 and 5. The basal CMRL-0.1X ITS serum-free
medium consisted of CMRL with 0.5 mg/L insulin+0.5 mg/L
transferrin+0.5 mg/L selenite (i.e. 0.1 times I-1884 from Sigma),
10 mM nicotinamide and 0.2% BSA (STEMCELL, BC, Canada).
The test solutions contained 0.1%, 1% or 10% FBS (Invitrogen), or
50% pancreatic fibroblast-conditioned medium diluted in CMRL-
0.1X ITS. The following recombinant human growth factors were
also tested at 20 ng/mL unless otherwise mentioned: basic fibroblast
growth factor (bFGF, STEMCELL), epidermal growth factor (EGF,
STEMCELL), hepatocyte growth factor (HGF, Sigma), keratinocyte
growth factor (KGF, Sigma), vascular endothelial growth factor
(VEGF, Sigma). One h after the last medium exchange, 10 mMo f5 -
Bromo-29-deoxy-uridine was added (BrdU, Labelling and Detection
Kit II, Roche, Basel, Switzerland) and incubated for 20 h prior to
fixing, staining and Cellomics analysis.
Conditioned medium
Passaged (P3 to P8) CD90-enriched pancreatic cells cultured in
CMRL+10% FBS medium until reaching 90% confluency
(,6610
4 cells/cm
2) were treated with 10 mg/mL mitomycin c
(Sigma) for 1 h, washed 3 times and incubated for 24 h in CMRL-
0.1X ITS, then filter-sterilized and stored at 280uC.
Cell dispersion
Cell clusters were washed twice with dispersion medium (1 mM
EDTA from Invitrogen, 10 mM HEPES from Sigma and 0.5%
bovine serum albumin from STEMCELL prepared in Ca
2+ and
Mg
2+-free HBSS from Invitrogen), then re-suspended at 0.05 mL
PCV/mL in dispersion medium and kept at 37uC for 7 min with
75 rpm agitation. Clusters were digested for 10 min at 37uCb y
adding 25 mg/mL trypsin and 4 mg/mL DNase (Sigma). After
adding CMRL+10% FBS medium, the cells were triturated and
filtered through a 40 mm nylon sieve (BD Biosciences). The total
cell yield based on PCV was 4367%, providing 168639 million
live dispersed cells/mL PCV initial tissue clusters.
Magnetic-activated cell sorting
Adherent cells from undispersed clusters were washed with
MACS buffer consisting of Ca
2+ and Mg
2+-free phosphate buffered
saline (PBS) with 1% FBS, 2 mM EDTA, 100 units/mL penicillin
and 100 mg/mL streptomycin. Cells were trypsinized, triturated
after adding CMRL+10% FBS medium and then filtered through a
40 mm cell strainer(BDBiosciences),yielding0.1760.05610
6 cells/
cm
2 on day 1. The cells were then washed twice with MACS buffer
and re-suspended at #2610
7 cells/mL in $50 mL MACS buffer.
An equal volume of primary antibody was added to obtain 1:100
mouse anti-Ca19-9 (#NCL-L-CA19-9, Leica Microsystems, Ger-
many)or1:500mouseanti-CD90(#555593,BDPharmingen,CA).
After incubating for 25 min on ice at 75 rpm agitation, the cells
were washed twice with MACS buffer. Magnetic labeling was
performed using microbead-labelled goat or rat anti-mouse IgG1
antibody (#130-048-402 or #130-047-102, Miltenyi Biotec,
Germany). Cells were re-suspended at 4610
6 cells/mL and
separated using the ‘‘possel’’ (for Ca19-9) or ‘‘depletes’’ (for
CD90) program of an AutomacsH (Miltenyi) cell separator. The
total live cell yield from MACS was 6063%.
Figure 1. Phenotype of dispersed unsorted islet-depleted
pancreatic cells cultured in serum-containing medium. On day
8, mixed cultures of CK19+ duct-like cells and vimentin+ fibroblast-like
cells with very rare amylase+ cells are obtained. After a single passage,
cultures consisted mainly of vimentin+ cells.
doi:10.1371/journal.pone.0033999.g001
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Adherent cells were washed with PBS, trypsinized, triturated
after adding FACS buffer (PBS+10% FBS) and filtered through a
40 mm strainer. Cells kept on ice were then washed twice with
FACS buffer, distributed to obtain 2.5610
5 cells/sample,
centrifuged and re-suspended in 50 mL. Then, 50 mL of primary
antibody diluted in FACS buffer (same concentrations as for
MACS) were added, followed by 25 min incubation at 75 rpm.
The cells were washed twice, re-suspended in 50 mL and 50 mLo f
Alexa 647 labelled goat anti-mouse IgG (A21450, Invitrogen) were
added to obtain a 1:200 dilution. After 15 min incubation in the
dark at 75 rpm, 10 mL of propidium iodide at 100 mg/mL (Sigma,
in PBS) was added. The cells were washed twice, re-suspended in
500 mL FACS buffer and analyzed on a BD FACSCalibur flow
cytometer. Data analysis including compensation was performed
with Flowjo 7.2.5 software (Tree Star, Ashland, OR).
Immunocytochemistry and Cellomics
Cell fixing and staining with BrdU was performed according to
the BrdU kit instructions (Roche), except for diluting primary and
secondary antibodies 1:20. For samples that did not require BrdU
labeling, the cells were fixed with Bouin’s fixative for 15 min and
stored in 70% ethanol. CK19 or Ki67 antigen retrieval was
performed by microwaving 6 times for 5 s at 1000 W in 10 mM
citrate (Sigma) at pH 6.0 and cells permeabilized by a 10 min
incubation in 0.25% Triton X 100 (Sigma) dissolved in PBS.
Unless otherwise mentioned, all subsequent incubations were at
room temperature and 100 rpm agitation. All samples were then
washed with PBS, incubated in blocking solution (Dakocyotma-
tion, Glostrup, Denmark) for 15 min and then stained overnight at
4uC with primary antibodies in Antibody Diluent (Dako). Primary
antibodies were 1:200 guinea pig anti-human insulin (Dako
A0564), 1:1000 rabbit anti-human amylase (Sigma A8273),
1:200 mouse anti-human CK19 (Dako M0888), 1:200 mouse
anti-human vimentin (Dako M0725), 1:50 rabbit anti-human Ki67
(Santa Cruz Biotech sc-15402, Santa Cruz, CA) and/or 1:200
mouse anti-human Ki67 (BD Biosciences 556003). The next day,
cells were washed with PBS and stained 1 h in the dark with
secondary antibodies (Alexa 488 goat anti-guinea pig IgG, Alexa
488 or 568 goat anti-rabbit IgG and/or Alexa 568 goat anti-
mouse IgG, all from Invitrogen) at 1:200 in Antibody Diluent.
Samples were then washed, stained with 1 mg/mL DAPI for
Figure 2. Evolution of cell populations after CD90 magnetic-activated cell sorting assessed by FACS.
doi:10.1371/journal.pone.0033999.g002
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Cellomics ArrayScan VTI. Slides were mounted with Vectashield
medium (Vector Labs, Burlingame, CA) and imaged on a Zeiss
Axioplan 2 microscope (Carl Zeiss, Oberkochen, Germany), using
ImageJ analysis software (NIH).
Design of experiments and statistical analysis
Results represent the average values obtained from 3 to 5
pancreata 6standard error of the mean. Two-way comparisons were
based on Student’s t-tests with p-values,0.05 considered significant,
with a paired t-test used in the case of the comparison between the
CK19+ cell number and BrdU incorporation read-outs. For
comparison between a basal response and responses normalized to
the basal response, confidence intervals with a levels of 0.05 were
used. The main and interaction effects of bFGF, EGF, HGF, KGF
a n dV E G Fw e r eq u a n t i f i e db yat w o - l e v e l( l o wl e v e l0n g / m L ;h i g h
level 20 ng/mL) full factorial design with 8 centre points (10 ng/mL
of all five factors). For each pancreas, these 40 conditions were
repeatedonthree96-wellplateswithdifferentrandomizationoneach
plate. The results were analyzed with JMP 7.0 or 8.0 statistics
software (SAS, Cary, NC). The growth factor concentrations Ci were
t r a n s f o r m e di n t os c a l e dv a r i a b l e sxi~
Ci{10
10
.T h em o d e lw a sa s
follows: Y~b0zbFxFzbExEz:::zbEFxExFz::: up to the fifth-
order interaction effect bEFHKVxExFxHxKxV,w h e r ebi values
represent the fitted model parameters. The subscripts F, E, H, K, V
represent the ‘‘i’’ factors bFGF, EGF, HGF, KGF and VEGF. The
model was then reduced to exclude factors with p-values.0.1.
Results
Cultures of human exocrine pancreatic tissue give rise to
duct-like epithelial cells and fibroblast-like cells
The cell types in islet-depleted cell clusters and derived adherent
cultures were assessed. The initial dispersed tissue (day 0) consisted
of 61616% amylase+ cells, 663% CK19+ cells, 1266% vimentin+
cells and 0.0460.01% insulin+ cells. The fraction of insulin+ cells
remained ,1% throughout the culture period. After 2 days of
adherent culture, the total adherent cell number was 27616% of
the cell number seeded, as expected for cultures containing
significant numbers of human acinar exocrine cells [28]. Most
CK19+ cells were in small clusters by day 2 (Figure 1), suggesting
that these cells proliferated within 2 days, were incompletely
dispersed or re-aggregated selectively. On the contrary, the
vimentin+ cells were dispersed as single cells. At day 8, the cultures
mainly consisted of duct-like cells in rounded cobblestone patterns
surrounded by fibroblast-like spindle-shaped cells. The remaining
amylase+ cells accounted for ,1% of the cells and appeared
unhealthy. Both main populations were proliferative at day 7
(44626% BrdU+ cells among CK19+ cells; 60624% BrdU+ cells
among vimentin+ cells). After a single passage (day 13), the cultures
consisted almost entirely of vimentin+ cells with rare CK19+ cells.
Magnetic-activated CD902 cell sorting removes
fibroblast-like cells
A negative cell selection strategy was developed to purify human
pancreatic exocrine cell cultures by removing CD90-positive cells.
After 7 days of adherent culture, 34620% of dispersed unsorted
islet-depleted pancreatic cells were labelled with CD90 antibodies
(Figure 2), a proportion similar to that of the spindle-shaped
fibroblast-like cells. In preliminary studies, CD90-depleted cells
obtained by MACS sorting on day 7 had ,2 fold higher CK19
mRNA and ,2.4 fold lower vimentin mRNA compared to the
CD90-enriched fraction (data not shown).
To remove fibroblast-like cells before they proliferate to become
a significant fraction of the cultured cells, islet-depleted cell clusters
were first plated, left to adhere overnight and sorted on day 1. Cell
dispersion after overnight adhesion had the advantage of being less
damaging (8564% cell viability after dispersion) than dispersion of
clusters on day 0 (7164% viability), without any significant
difference in the viable cell yield (166672 million cells/mL initial
PCV). The cell phenotypes obtained after CD90 sorting on day 1
are shown in Figures 2 and 3 as well as in Table 1. Depletion
reduced the fraction of CD90+ cells on day 1 from 867% to
0.0660.01%. After 7 days of culture, the unsorted cells consisted
of a ,40/60 mixture of Ca19-9+ and CD90+ cells whereas the
CD90-depleted cultures consisted of .85% Ca19-9+ cells
(Figure 2). On day 8, the CD90-depleted cell cultures consisted
mainly of CK19+ cells growing in cobblestone patterns typical of
epithelial cells, while the CD90-enriched cultures consisted mainly
of spindle-shaped fibroblast-like vimentin+ cells (Figure 3). Com-
pared to unsorted tissue, CD90 depletion doubled the fraction of
CK19+ cells on day 8, similar to the CK19+ fraction obtained by
enrichment of cells expressing the Ca19-9 duct surface marker.
Although a higher proportion of amylase+ cells were seeded by
CD90 depletion than by Ca19-9-enrichment, there were no
significant differences in the cell phenotypes obtained on day 8
(Figure 3 and Table 1). When enriched amylase+ cells obtained by
Figure 3. Phenotype of MACS-sorted cultures. The CD90-enriched
or Ca19-9 depleted cell fractions generate cultures of spindle-shaped
vimentin+ cells; while the CD90-depleted and Ca19-9 enriched fractions
generate cobblestone-pattern CK19+ cells. Culture time: 8 days.
doi:10.1371/journal.pone.0033999.g003
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the number of viable cells enumerated on day 9 was ,1% of the
number of CK19+ cells in CD90-depleted cultures (data not
shown), indicating that most amylase+ cells do not persist until day
8 in adherent cultures.
Development of a screening platform to optimize duct
cell expansion
Next we sought to identify factors capable of promoting human
CK19+ cell expansion and to develop a serum-free medium for
CK19+ cell culture. Cells in the negative controls were cultured in
serum-free basal medium, while FBS or the reported duct mitogen
EGF were added to the positive controls. Two responses after
culture were quantified: the number of CK19+ cells (Figure 4A), or
the BrdU incorporation by CK19+ cells (Figure 4B). The cell
expansion rate varied between pancreata. To render the results
between pancreata more comparable and to avoid saturation of
the CK19+ cell number read-out, all cultures were ended when
cells in the 10% FBS control reached confluency. The amplitude
of the response to FBS was significantly higher (p=0.005, paired t-
test for the 0.1%, 1% and 10% FBS responses) for the BrdU
response than for the CK19+ cell number. In addition, contrary to
the CK19+ cell number, BrdU incorporation was consistently
increased in the 10% FBS positive control condition for all 6
pancreata, even for the 2 pancreata where confluency (,5000
cells/well) was reached by day 6. Another consideration addressed
in these experiments was whether soluble factors secreted by the
fibroblast-like CD90+ cells affected CK19+ cell expansion. The
addition of 50% conditioned medium from passaged CD90-
enriched cells tended to increase both the number and the BrdU
incorporation of CK19+ cells. This complicated data interpreta-
tion especially for unsorted cultures because the CK19+ cell results
could be indirectly influenced by factors produced by the large
fraction of vimentin+ cells in these cultures (Figure 1). Based on
these observations, screening experiments aiming to maximize
CK19+ cell expansion were performed on CD90-depleted cell
populations, using BrdU incorporation by CK19+ cells between
days 5 and 6 as the measured response.
Multifactorial screening to optimize CK19+ cell expansion
The methodology developed was then applied to test the full
factorial effects of five growth factors: bFGF, EGF, HGF, KGF
and VEGF, using a total of 120 cultures and 3 pancreata to
systematically determine the main and interaction effects of these
factors. In this case, the culture time was kept constant at 6 days to
simplify experimental planning and since none of the previous
cultures (Figure 4) reached confluency before day 6. The high level
growth factor concentrations selected for the factorial experimen-
tal design (20 ng/mL for each growth factor) were based on
growth factor concentrations reported to increase duct cell
expansion (Table 2.1 in reference [29]). Figure 5A shows the
values of the scaled model parameters bi, obtained by least squares
fitting. The raw data of the full factorial experiment, including
other read-outs such as the fraction number of CK19+ or
vimentin+ cells is provided as supporting information in JMP
(Dataset S1) and comma-separated values (Dataset S2) formats.
Statistical analysis software (e.g. JMP) can be used to determine the
read-outs predicted for various growth factor combinations and
concentrations. The model described by Figure 5A was then
reduced to include only the significant (p,0.05 in Figure 5A)
parameters. No significant lack-of-fit was detected, indicating that
the reduced model predicted the data within the experimental
error, as can be seen in Figure 5B. The reduced model equation
using scaled growth factor concentrations was:
Y~2:18z0:33xFz0:32xEz0:24xHz0:23xKz
0:28xExVz0:20xFxHxKxV
ð1Þ
where Y represents the fold increase in BrdU incorporation by
CK19+ cells relative to the read-out in the presence of basal
medium and xi are the growth factor concentrations scaled
between 21 (0 ng/mL) and 1 (20 ng/mL). In this equation and
Table 1. Fractions of cells obtained before and after sorting on day 1.
Cell population Day seeded Day analyzed % positive cells by immunocytochemistry % positive cells by FACS
Amylase CK19 Vimentin CD90 Ca19-9
Unsorted 0 0 61616
b 6 631 2 66 N/A N/A
Unsorted 0 1 47617 2266
a 1164
a 867
a 54616
CD902 01 4 2 610 1866
a 862
a 0.0660.01
a N/A
CD90+ 01 1 9 651 2 66
a 42618
a 26610
a N/A
Ca19-9+ 01 1 6 685 1 621
a 262
a N/A 9662
Ca19-92 01 7 2 614 562
a 2469
a N/A 14613
Unsorted 0 8 0.6
c 32671 8 611 48618 46620
Unsorted 1 8 0.5
c 36610 21652 7 69
a 60611
a
CD902 18 2 . 3
c 59641 0 62 0.760.4
a 7968
a
CD90+ 18 7 . 4
c 16635 4 621 84631 4 61
b
Ca19-9+ 18 0 . 6
c 55610 762 0.760.2
b 9364
b
Ca19-92 18 0 . 5
c 25610 48618 6769
b 461
b
Note: unless otherwise indicated, the number of replicates is N=3 pancreata.
aNumber of replicate pancreata=4.
bNumber of replicate pancreata=2.
cNumber of replicate pancreata=1.
N/A=non-available.
doi:10.1371/journal.pone.0033999.t001
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(Figure 5A), it can be seen that bFGF, EGF, HGF and KGF each
exerted significant positive main effects on CK19+ cell BrdU
incorporation. Two significant interaction effects were also
identified between EGF and VEGF, as well as bFGF, HGF,
KGF and VEGF, indicating that in these combinations VEGF
addition did have a positive effect. Conversely, a significant
negative effect of VEGF would be expected in the absence of the
other factors in these combinations (i.e. adding VEGF without also
adding EGF or bFGF, HGF and KGF). Figure 5B compares the
reduced model prediction to the measured fold increases in
CK19+ cell BrdU incorporation for all growth factor combina-
tions. Both the raw data and the model indicate that the
combination of factors that promoted the highest CK19+ cell
proliferation was the addition of all five factors (at 20 ng/mL
each), but with .70% of this effect achieved by the FH (bFGF and
HGF) or FK (bFGF and KGF) combinations. It should be noted
that EGF and HGF were also found to have significant negative
effect on the %CK19+ cells for each pancreas, respectively leading
to 261% and 361% decrease in the 69611% fraction of CK19+
cells observed if no growth factors were added (N=3 pancreata).
The effect of the bFGF, EGF, HGF and KGF (FEHK, at 20 ng/
mL each) growth factor combination on CK19+ cell expansion
was further examined in a time-course experiment with replicate
cultures of cells from one pancreas. Figure 6A shows that the
FEHK growth factor cocktail did significantly increase net CK19+
cell numbers compared to the basal medium and yielded CK19+
cell numbers equal or superior to those obtained with 10% FBS.
The cultures obtained in the FEHK serum-free conditions
retained the cobblestone pattern morphology typical of pancreatic
duct cell cultures (Figure 6B).
Figure 4. Validation of a screening platform to identify CK19+
cell mitogens. A) Number of CK19+ cells at the end of the culture
normalized to the number obtained in basal serum-free medium
culture. B) Fraction of CK19+ cells that incorporated BrdU during the
last day of culture, normalized to BrdU incorporation in basal medium
culture. Unsorted cells were seeded on day 0 while CD90-depleted cells
were sorted and seeded on day 1. The data were pooled from cultures
ending on day 8 (N=5 pancreata) or day 6 (N=3 pancreata) and
normalized for each pancreas prior to calculating averages and errors.
The non-normalized results obtained at the end of the cultures in basal
medium were as follows: the unsorted populations contained
0.0560.02610
5 CK19+ cells/cm
2 of which 663% were BrdU+; the
CD90-depleted populations contained 0.0760.02610
5 CK19+ cells/cm
2
of which 1.060.6% were BrdU+.* p ,0.05 compared to basal medium.
doi:10.1371/journal.pone.0033999.g004
Figure 5. The 2
5 full factorial effects of reported duct mitogens
on CK19+ cell proliferation. The mitogens tested were bFGF (F), EGF
(E), HGF (H), KGF (K) and VEGF (V) and the response measured was the
fraction of BrdU+ cells among CD90-depleted CK19+ cells. A) Scaled
parameter estimates of the full factorial model (*p,0.05). The
‘‘pancreas’’ effect, considered as a non-interacting independent
variable, was non-significant and is not shown. Here, F, E, H, K and V
represent their respective effects (bi) in the factorial model, divided by
the b0 intercept. B) Comparison between the experimental data and the
reduced factorial model prediction for each combination. Here, F, E, H, K
and V represent the addition of 20 ng/mL of each growth factor (e.g.
the HK combination represents the addition of 20 ng/mL HGF and
20 ng/mL KGF without any other growth factors added). The values of
the model predictions represent the value calculated from Equation 1 6
standard error of the model. The data were generated from N=3
pancreata cultured for 6 days. The dataset used to generate this figure
is provided as supporting information in JMP (Dataset S1) and comma-
separated values (Dataset S2) formats.
doi:10.1371/journal.pone.0033999.g005
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The study and medical use of duct-like cells derived from the
pancreatic tissues discarded during islet transplantation is
hampered by fibroblast-like cell overgrowth and the need for an
optimized defined serum-free medium for duct-like cell expansion.
We present a novel method to deplete fibroblast-like cells from
pancreatic tissue using CD90-based selection, as well as a serum-
free high content screening platform to identify pancreatic duct
mitogens.
Human duct-like cells can reportedly be maintained in culture
for up to 5 weeks with fibroblast overgrowth avoided by selective
cell scraping [30]. However, this would normally not be practical
for larger experiments and requires human pancreatic duct
dissection rather than the simpler use of the tissue discarded after
islet transplantation. Pre-plating reduces but does not sufficiently
eliminate contaminating fibroblast-like cells [10]. Treatment with
G418 yields purified endothelial cell cultures [31], but non-
specifically affects all cycling cells. Fluorescence or magnetic-
activated cell sorting of CA19-9 expressing cells generates purified
duct cell cultures without contribution from acinar cells [23].
However, for studies related to diabetes cellular therapy or
pancreatic cancer research, the CK19+/Ca19-9+ cells arising
from acinoductal transdifferentiation are of interest since they may
generate insulin+ cells [32,33] or cancer precursors [34]. In our
work, CD90 was used to deplete fibroblast-like cells [20] but not
acinar cells from islet-depleted pancreatic cell clusters. After one
week, magnetically sorted CD90+ cells yielded fibroblast-like
vimentin+ cells, while the reseeded CD902 cells yielded CK19+
cells with epithelial morphology (Figure 3) that contained virtually
no CD90+ cells.
The CD90 depletion strategy was compared to the conventional
Ca19-9+ cell enrichment. On day 8, there was no significant
difference between the number or the fraction of CK19+ cells
obtained by CD90 depletion and Ca19-9 enrichment. Yet, the
initial CK19+ cell number seeded was 2.5 fold lower for the
CD902 sorted cells compared to the Ca19-9+ sorted cells due to
the presence of acinar cells in the CD902 sorted population. It is
possible that molecules released by lysing amylase+ cells [35] or
contaminating endocrine cells [36] increased the CK19+ cell
proliferation in the CD90-depleted cultures by mechanisms similar
to those occurring after pancreas injury [37], or that the presence
of antibodies on the surface of the Ca19-9+ cells decreased their
proliferation or survival. It has been suggested that acinar cells can
also give rise to CK19+ cells in pancreatic cultures [33,34,38,39].
However, we enumerated very few viable cells when we cultured
purified acinar cells obtained by CD90 and Ca19-9 co-depletion.
Similar to other reports of selective human pancreatic acinar cell
death [28,40], we did not observe any amylase+ cells co-stained
with CK19, and the amylase+ cells appeared apoptotic based on
their condensed nuclei [41]. These observations suggest that the
CK19+ cells in the CD90-depleted cultures mainly arose from
duct cells rather than transdifferentiated acinar cells.
A Cellomics-based imaging method was used to screen CK19+
cell mitogens and develop a serum-free medium adapted to these
cells. CD90-depleted cells were used to avoid measuring indirect
effects exerted by vimentin+ cells on the CK19+ cells. Factorial
design [42,43,44,45] increased the statistical power of experiments
and reduced the number of runs required to elucidate factor
interaction effects compared to performing a series of two-way
comparisons [46]. The positive main effects of bFGF, EGF, HGF
and KGF observed are consistent with their reported effects on
normal [47,48,49,50,51] and neoplastic [52] ductal cells. Pancre-
atic knock-down of the bFGF [53] or the EGF receptor impairs
embryonic ductal growth and branching morphogenesis. EGF
treatment increases the proliferation of embryonic pancreatic
epithelial cells in vitro [54] and leads to pancreatic duct hyperplasia
when administered to adult pigs [55]. The secretion of KGF [56]
[57,58] and HGF [59] [60] by the embryonic pancreatic
mesenchyme induces the expansion of early pancreatic epithelial
progenitors [61]. The effect of VEGF was less clear, decreasing
CK19+ cell proliferation by ,70% when added alone and
reducing the mitogenic effects of other factors in several 3-factor
combinations, and yet increasing CK19+ cell proliferation when
all factors were added together. VEGF has been shown to increase
the proliferation of fetal [62] and adult [63] rat pancreatic
endothelial cells in vitro, but did not have a significant effect on
adult human islet-depleted tissue in suspension cultures [28]. The
interaction effects involving VEGF that were uncovered by the
factorial experiment could explain the disparity between the
reported in vitro effects of VEGF on duct cells (i.e. because they
depend on the other factors present in the culture medium). Some
confusion over the effects of VEGF on duct cells in vitro may also
arise from indirect effects of VEGF on mesenchymal cells [64],
further underlining the importance of cell sorting strategies to
assess the direct effects on the population of interest.
The methods developed in this work can be applied to a variety
of studies involving primary human pancreatic and other tissues.
In particular, CD90 depletion provides a useful tool to resolve
pancreatic cell populations. For example, Ca19-9 and CD90 co-
Figure 6. CK19+ cell expansion in medium containing bFGF,
EGF, HGF and KGF compared to control media. A) Growth curve
based on the number of CK19+ cells enumerated at different time
points in the presence of 20 ng/mL each of bFGF, EGF, HGF and KGF or
control media (*p,0.05 for two-way comparisons with the 10% FBS
condition). B) Phase contrast images of the cultures taken on day 6.
N=1 pancreas with 6 replicate cultures.
doi:10.1371/journal.pone.0033999.g006
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depleted tissue. CD90-depletion could also be useful to eliminate
fibroblast-like cells from dispersed human islets by removing CD90
and C19-9 expressing cells in a single step prior to NCAM+
sorting [65]. The high content duct-mitogen screening platform
could be used to further optimize pancreatic CK19+ cell culture
conditions, such as for testing other growth factors, basal media,
alternative medium additives or culture surfaces. The factors in
CD90-cell conditioned medium that cause an increased prolifer-
ation of the CK19+ cells could be identified by fractionation and
mass spectrometry. Also, the bFGF, EGF, HGF and KGF-
supplemented serum-free medium or other promising combina-
tions such as bFGF and HGF or bFGF and KGF could be used in
protocols requiring the serum-free expansion of pancreatic CK19+
cells. The optimal concentrations of these growth factors could be
investigated by more complex multidimensional dose response
studies, for example using central composite experimental design
[42]. The CD90-depleted cell culture platform could be used in a
variety of high content screening studies, such as to identify
molecules that hinder the proliferation of pancreatic cancer cells,
but not normal duct cells.
In conclusion, we describe a novel CD90 magnetic-activated
cell depletion strategy to generate purified CK19+ cell cultures
from primary human islet-depleted pancreatic tissue. Multifacto-
rial high content screening of the bFGF, EGF, HGF, KGF and
VEGF effects uncovered significant interactions between these
factors. The growth factor combination that maximized the
expansion of CK19+ cells in serum-free medium included the
addition of all five factors (at 20 ng/mL concentration for each
factor), whereas the combination of bFGF and HGF, or the
combination of bFGF and KGF achieved ,70% of the maximum
effect. Several areas of diabetes and pancreatic cancer research
could benefit from these methods to obtain purified CK19+
pancreatic cells in serum-free cultures amenable to high content
screening.
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5 full factorial
effects of reported duct mitogens on CK19+ cell
proliferation (Figure 5). This dataset provides the cell number,
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